• DNDi_Logo_No-Tagline_Full Colour
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Parasitic worms
      • Mycetoma
      • Dengue
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Pandemic preparedness
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Evidence for impact
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies and IP
      • Children’s health
      • Gender equity
      • Climate change
      • AI and new technologies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • Dengue Alliance
      • HAT Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
      • DNDi West and Central Africa
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
      • Podcasts, radio & TV
      • Media workshops
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • Our story
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
      • Our prizes and awards
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
  • DNDi_Logo_No-Tagline_Full Colour
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Parasitic worms
      • Mycetoma
      • Dengue
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Pandemic preparedness
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Evidence for impact
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies and IP
      • Children’s health
      • Gender equity
      • Climate change
      • AI and new technologies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • Dengue Alliance
      • HAT Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
      • DNDi West and Central Africa
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
      • Podcasts, radio & TV
      • Media workshops
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • Our story
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
      • Our prizes and awards
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
Home > Diseases
Mosquito icon

Dengue

Developing urgently needed treatments for a rapidly spreading climate-sensitive disease

Home > Diseases
Mosquito icon

Dengue

Developing urgently needed treatments for a rapidly spreading climate-sensitive disease

  • Overview
  • Facts
  • Projects & achievements
  • Target product profile

We established the Dengue Alliance, a global partnership of leading public health institutes, to discover and develop new treatments effective against the disease. Together, we are actively searching for new treatments and have advanced promising candidates to clinical trials. Our teams and partners are also carrying out much-needed research on the under-reported burden of dengue in Africa.

Dengue is mostly spread by the bite of the Aedes aegypti mosquito. Some people have no symptoms, but dengue can also cause fever, nausea, vomiting, rashes, fatigue, and intense eye, muscle, joint, and bone pain. For some, dengue infection can become severe, with complications such as bleeding and plasma leakage that can lead to shock, organ dysfunction, and death. Pregnant women, children, older adults, and people with comorbidities are most at risk.

Driven by climate change, rapid urbanization, and increased population mobility, dengue is the most widely distributed and rapidly spreading mosquito-borne viral disease in the world. Despite promising innovation in vaccines and vector control, dengue incidence continues to rise across endemic regions, and new areas are increasingly threatened, exposing a major and persistent gap in patient care: the absence of approved, effective treatments that can stop dengue progression and prevent severe illness.  

Icon people in front of globe
of the world’s population lives in areas at risk
> 0 %
Icon parasite
infections reported in 2024 – the highest on record
> 0 million
Icon globe with location
of cases reported in the Americas
0 %
DOWNLOAD FACT SHEET
SEE DISEASE FACTS

‘I thought I was going to die. When I opened the gate to get out, I fell down the stairs. I couldn’t stand. If there was a special medication for dengue, I would take it. What I’m feeling – I wouldn’t wish this on anyone, even my enemy.’

Mauricio lives in the community of Morro de Prazeres in Rio de Janeiro, Brazil. When he had dengue, he struggled to climb the stairs up the 275-meter-tall hill Morro dos Prazeres is built on.
Our short film ‘Treating a feverish planet: The Dengue Alliance’ takes us to Brazil, Sri Lanka, and Thailand to show the devastating impact dengue outbreaks are having across the world.  

watch film

What we have achieved

We are bringing together partners in dengue-endemic countries to find urgently needed treatments for dengue.

Loading…

Dengue Alliance

We established the Dengue Alliance, a global partnership of leading public health institutes in key endemic countries, to discover and develop new treatments for dengue.

What we’re doing for people with dengue

Together with our partners, we have started preclinical studies and will be starting clinical trials aiming to deliver an affordable and accessible treatment within five years. We are also working together on diagnostics and regulatory and access strategies, as well as jointly raising funds and mobilizing resources.

Read more in our Annual Report
Loading…
Translational research

Dengue pre-clinical profiling

We are working with partners to repurpose existing direct-acting antivirals and host-directed therapies capable of inhibiting the inflammatory response characteristic of severe disease. DNDi teams are also working with partners to develop new antivirals effective against the dengue virus.

Dengue seroprevalence and burden studies

DNDi and partners are conducting retrospective dengue seroprevalence studies in Senegal, Ghana, and the Democratic Republic of the Congo (DRC) to better understand the burden of the disease in Africa and inform vaccine and vector-control strategies, as well as future treatments.

Drug discovery

AI-guided discovery

Scientists from DNDi and BenevolentAI use an artificial intelligence-driven approach to interrogate the underlying mechanisms involved in dengue and rapidly identify therapies that could be repurposed to prevent progression to severe dengue.

Dengue news & resources

Loading…
filter by
ALL
News
Press releases
Publications
Scientific articles
Stories
Videos
Viewpoints
News
2 Nov 2026

Project to develop dengue treatment pre-selected by the Global Coalition for Local and Regional Production, Innovation, and Equitable Access

Press releases
27 Oct 2026

Kenya becomes first African country to join the Dengue Alliance

Scientific articles
10 Oct 2026

Rethinking Clinical Trial Design to Accelerate Therapeutics for Arboviral Epidemics

Open Forum Infectious Diseases
Publications
16 Jul 2026

DNDi 2025 Annual Report

See all news

Making medical history for neglected patients

We develop urgently needed treatments for neglected patients and ensure they’re affordable, available, and adapted to the communities who need them

Chagas disease

Causes heart and vital organ damage, after people are bitten by blood-sucking bugs

We delivered the first-ever treatment for children; now we’re searching for new drug candidates and working to boost access to care

Patient medical examination

Cryptococcal meningitis

Without treatment, deadly for thousands of people with advanced HIV

We’re working to improve access to life-saving treatments and developing an easier-to-use formulation

Cutaneous leishmaniasis

Leaves disfiguring, life-long scars that lead to severe social stigma

We’re working to develop safer, shorter treatments for this disabling disease

Dengue

Rapidly spreading climate-sensitive disease with no specific treatment

We’re building a global partnership with dengue-endemic countries to develop a first treatment

Hepatitis C

Millions are left without treatment even though effective drugs exist

We’ve delivered a treatment as simple, safe, and effective as the best drugs available today – at a fraction of the cost 

Mycetoma

Often ends in amputation​, after people get infected from stepping on a thorn

We conducted the world’s first trial for an alternative to current treatments, which are toxic and difficult to administer

Paediatric HIV

Without treatment, half of children die before their second birthday

We’ve developed a strawberry-flavoured treatment to meet the needs of children long neglected by the global HIV response

Healthcare workers in a hospital

Pandemic preparedness and response

COVID-19 threw longstanding global health injustices into stark relief

We’re conducting research for new drugs before the next pandemic strikes and advocating for equitable innovation and access

Parasitic worms

Cause debilitating illness, social exclusion, and long-term disability

We’re working across multiple diseases to develop missing cures that can prevent lasting harm

Sleeping sickness

Transmitted by the bite of a tsetse fly and causes severe neurological disorders

We delivered a revolutionary new drug to replace toxic treatments, and have ongoing trials to eliminate this disease

Visceral leishmaniasis

Is one of the world’s biggest parasitic killers, spread by the bites of sandflies

We’re working to develop a new generation of treatments to replace drugs that are painful, ineffective, and cause side effects

Chagas disease

Cryptococcal meningitis

Cutaneous leishmaniasis

Dengue

Hepatitis C

Mycetoma

Paediatric HIV

Pandemic preparedness and response

Parasitic worms

Sleeping sickness

Visceral leishmaniasis

VIEW ALL DISEASES

Stay connected

Get our latest news, personal stories, research articles, and job opportunities. 

Linkedin-in Instagram Youtube Tiktok Facebook-f
International non-profit developing safe, effective, and affordable treatments for the most neglected patients.

Learn more

  • Diseases
  • Neglected tropical diseases
  • R&D portfolio
  • Policy advocacy

Get in touch

  • Our offices
  • Contact us
  • Integrity Line

Support us

  • Donate
  • Subscribe to eNews

Work with us

  • Join research networks
  • Jobs
  • RFPs
  • Terms of Use   
  •   Acceptable Use Policy   
  •   Privacy Policy   
  •   Cookie Policy   
  •   Our policies   

  • Except for images, films, and trademarks which are subject to DNDi’s Terms of Use, content on this site is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International license